<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024231</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-004</org_study_id>
    <secondary_id>(MDX1106-04)</secondary_id>
    <nct_id>NCT01024231</nct_id>
  </id_info>
  <brief_title>Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma</brief_title>
  <official_title>A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medarex</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ono Pharma USA Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of treatment with
      BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time
      or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant
      melanoma (MEL)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 14, 2009</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 7, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessments will be based on adverse event reports and the results of clinical laboratory tests, immune safety tests, physical examinations, vital sign measurements, ECOG performance status, and ECG evaluations</measure>
    <time_frame>Up to 12 weeks after the last dose of the last study drug dose (approximately up to 5.5 years)</time_frame>
    <description>Eastern Cooperative Oncology Group (ECOG), electrocardiogram (ECG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic peak and trough concentration of each study drug when given in combination together or in a sequenced regimen</measure>
    <time_frame>Cohorts 1-5: Day 1, 2, 3, 8, 15, 22, 43, 64, 85, 106, 127, 148, 169, 253 &amp; 6 &amp; 12 weeks after last dose of study drug. Cohort 6-7: Day 1, 57, 113, 225, 337, 449, 561 &amp; 6 &amp; 12 weeks after last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples to test immunogenicity</measure>
    <time_frame>Cohorts 1-5: Pre-dose at weeks 0, 6, 12, 21, 24, 36, 60, 84, 108, and 12 weeks after last dose of study drug. Cohorts 6-7: Pre-dose at weeks 1, 9, 18, 36, 54, 72, 90, 108, 126, 144, 162, 180, and 12 weeks after last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response evaluations</measure>
    <time_frame>Cohorts 1-5: At weeks 12, 18, 24, 30, 36, 48, 60, 72, 84, 96 and 108. Cohorts 6-7: At weeks 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 108, 120, 132, 144, 156, 168, 180</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: BMS-936558 (0.3 mg/kg)+Ipilimumab (3 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-936558 (MDX1106-04) 0.3 mg/kg solution, 60 minutes intravenous infusion every 3 (q3) weeks for 21 weeks in induction and every 12 (q12) weeks for 84 weeks in maintenance
Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: BMS-936558 (1 mg/kg)+Ipilimumab (3 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance
BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: BMS-936558 (3 mg/kg)+Ipilimumab (3 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance
BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: BMS-936558 (10 mg/kg)+Ipilimumab (3 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance
Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: BMS-936558 (10 mg/kg)+Ipilimumab (10 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance
Ipilimumab (BMS-734016) 10 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: BMS-936558 (1 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: BMS-936558 (3 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: Nivolumab+Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg solution intravenously q3 weeks, 4 doses for 12 weeks
Followed by Nivolumab 3 mg/kg solution alone intravenously q2 weeks, 48 doses for a maximum of 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-936558 (MDX1106-04)</intervention_name>
    <arm_group_label>Cohort 1: BMS-936558 (0.3 mg/kg)+Ipilimumab (3 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 2: BMS-936558 (1 mg/kg)+Ipilimumab (3 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 3: BMS-936558 (3 mg/kg)+Ipilimumab (3 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 4: BMS-936558 (10 mg/kg)+Ipilimumab (3 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 5: BMS-936558 (10 mg/kg)+Ipilimumab (10 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 6: BMS-936558 (1 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 7: BMS-936558 (3 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 8: Nivolumab+Ipilimumab</arm_group_label>
    <other_name>Nivolumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Cohort 1: BMS-936558 (0.3 mg/kg)+Ipilimumab (3 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 2: BMS-936558 (1 mg/kg)+Ipilimumab (3 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 3: BMS-936558 (3 mg/kg)+Ipilimumab (3 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 4: BMS-936558 (10 mg/kg)+Ipilimumab (3 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 5: BMS-936558 (10 mg/kg)+Ipilimumab (10 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 8: Nivolumab+Ipilimumab</arm_group_label>
    <other_name>BMS-734016</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histologic diagnosis of malignant melanoma (MEL)

          -  Measurable unresectable Stage III or IV MEL

          -  ECOG performance status score of 0 or 1

          -  Life expectancy ≥4 months

          -  For those enrolled in amendment 5 and later, tumor tissue (archival or recent
             acquisition) must be available

          -  For Cohorts 1-5, subjects may have been treated with up to 3 prior systemic standard
             treatments for metastatic melanoma not including any post-incisional adjuvant therapy.
             Subjects may be treatment naïve. All metastatic melanoma regardless of primary site of
             disease will be allowed

          -  For Cohorts 6-7, subjects may have been treated with up to 3 prior systemic standard
             treatments for metastatic melanoma; this does not include any post-incisional adjuvant
             therapy. Specifically, subjects must have received ≥3 doses of Ipilimumab therapy and
             the last dose having been administered within 4-12 weeks of initiation of study
             treatment

        Exclusion Criteria:

          -  History of severe hypersensitivity reactions to other mAbs

          -  Prior malignancy active within the previous 2 years except for localized cancers that
             are considered to have been cured and in the opinion of the investigator present a low
             risk for recurrence

          -  Active autoimmune disease or a history of known or suspected autoimmune disease

          -  History of recently active diverticulitis or symptomatic peptic ulcer disease and
             history of adrenal insufficiency

          -  Regular narcotic analgesia

          -  Active, untreated central nervous system metastasis

          -  For subjects enrolled in Cohorts 1-5, prior therapy with an anti-PD-1, anti-PD-L1,
             anti-PD-L2, anti-CD137 or anti-CTLA-4 antibody

          -  For subjects enrolled in Cohorts 6-7, prior therapy with an anti-PD-1, anti-PD-L1,
             anti-PD-L2, or anti-CD137 antibodies

          -  Any non-oncology vaccine therapy used for prevention of infectious disease

          -  Concomitant therapy with any other anti-cancer therapy, concurrent medical conditions
             requiring use of immunosuppressive medications or use of other investigational drugs

          -  Positive tests for human immunodeficiency virus (HIV), acquired immunodeficiency
             syndrome (AIDS), hepatitis B, hepatitis C

          -  Subjects weighing ≥125 kg are excluded from Cohort 5

          -  Subjects in Cohorts 6 and 7 must have received Ipilimumab monotherapy immediately
             prior to study entry, but must not have received that Ipilimumab as part of a clinical
             trial

          -  Subjects with ocular melanoma are excluded from Cohort 8
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School Of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Georgetown-Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Research Pavilion</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

